Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2017
This report can be delivered to the clients within 25 Hours
DelveInsight’s, “Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market, and Pipeline Analysis, 2017” report provides comprehensive insights of the ongoing therapeutic research and development across mechanism of action. The report provides information on all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well as discovery products. Furthermore, the report also contains detailed information of marketed products along with historical and forecasted sales.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by the DelveInsight team of industry experts.Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
The report comprehensively includes:
DelveInsight’s, “Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market, and Pipeline Analysis, 2017” report provides comprehensive insights of the ongoing therapeutic research and development across mechanism of action. The report provides information on all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well as discovery products. Furthermore, the report also contains detailed information of marketed products along with historical and forecasted sales.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by the DelveInsight team of industry experts.Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
The report comprehensively includes:
- In-depth analysis of the 28+ pipeline assets and 5 marketed products
- Therapeutic assessment by molecule type, route of administration, monotherapy and combination products
- Licensing, Deals and Patent details (marketed and pipeline) related to HDAC inhibitors are also covered
- Insights on marketed products including detailed marketed product profiles. Also, includes Historical and Forecasted sales for Marketed products
- Information on various technologies involved in the development of pipeline therapeutics along with drug designations is also provided
Executive Summary
Overview
Competitive Landscape
Collaboration
Technology
Designation
Active Pipeline coverage by Indication
Marketed and Pipeline Drugs
Marketed Drug Profiles
Farydak: Novartis
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Farydak Global Sales
Farydak Analyst Insights
Beleodaq: Spectrum Pharmaceuticals
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Beleodaq Global Sales
Beleodaq Analyst Insights
Epidaza: Chipscreen Bioscience
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Epidaza Analyst Insights
Zolinza: Merck
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Zolinza Global Sales
Zolinza Analyst Insights
Istodax: Gloucester Pharmaceuticals
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Istodax Global Sales
Istodax Analyst Insights
Market Positioning of HDAC Inhibitors
HDAC Inhibitors Market Evaluation
HDAC Inhibitors Class Share Evaluation
Pipeline Therapeutics
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Entinostat: Syndax Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Pracinostat: MEI Pharma
Product Description
Research and Development
Product Development Activities
Givinostat: Italfarmaco
Product Description
Research and Development
Product Development Activities
Mid-Stage Products (Phase II)
Comparative Analysis
Mocetinostat: Mirati Therapeutic
Product Description
Research and Development
Product Development Activities
Quisinostat: Janssen
Product Description
Research and Development
Product Development Activities
VRx-3996: Viracta Therapeutics
Product Description
Research and Development
Product Development Activities
Sulforadex: Evgen Pharma
Product Description
Research and Development
Product Development Activities
CHR 5154: Chroma Therapeutics
Product Description
Research and Development
Product Development Activities
CUDC 907: Curis
Product Description
Research and Development
Product Development Activities
Ricolinostat: Celgene Corporation
Product Description
Research and Development
Product Development Activities
Remetinostat: TetraLogic Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Abexinostat: Celera Genomics Group
Product Description
Research and Development
Product Development Activities
Resminostat: 4SC
Product Description
Research and Development
Product Development Activities
FRM 0334: FORUM Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I)
Comparative Analysis
Citarinostat: Celgene Corporation
Product Description
Research and Development
Product Development Activities
AR-42: Arno Therapeutics
Product Description
Research and Development
Product Development Activities
EDO S101: Mundipharma International
Product Description
Research and Development
Product Development Activities
Pre-clinical Products
Comparative Analysis
PCI-34051: Pharmacyclics
Product Description
Research and Development
Product Development Activities
HG 3001: HitGen
Product Description
Research and Development
Product Development Activities
CG-1255: CircaGen Pharmaceutical
Product Description
Research and Development
Product Development Activities
CG-1521: CircaGen Pharmaceutical
Product Description
Research and Development
Product Development Activities
Trichostatin A: Errant Gene Therapeutics
Product Description
Research and Development
Product Development Activities
QTX-125: Quimatryx
Product Description
Research and Development
Product Development Activities
QTX-153: Quimatryx
Product Description
Research and Development
Product Development Activities
ACY 1083: Regenacy Pharmaceuticals
Product Description
Research and Development
Product Development Activities
ACY-738: Celgene Corporation
Product Description
Research and Development
Product Development Activities
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Institutional Products
Inactive Products
Comparative Analysis
Market Drivers and Barriers
Appendix
Overview
Competitive Landscape
Collaboration
Technology
Designation
Active Pipeline coverage by Indication
Marketed and Pipeline Drugs
Marketed Drug Profiles
Farydak: Novartis
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Farydak Global Sales
Farydak Analyst Insights
Beleodaq: Spectrum Pharmaceuticals
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Beleodaq Global Sales
Beleodaq Analyst Insights
Epidaza: Chipscreen Bioscience
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Epidaza Analyst Insights
Zolinza: Merck
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Zolinza Global Sales
Zolinza Analyst Insights
Istodax: Gloucester Pharmaceuticals
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Istodax Global Sales
Istodax Analyst Insights
Market Positioning of HDAC Inhibitors
HDAC Inhibitors Market Evaluation
HDAC Inhibitors Class Share Evaluation
Pipeline Therapeutics
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Entinostat: Syndax Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Pracinostat: MEI Pharma
Product Description
Research and Development
Product Development Activities
Givinostat: Italfarmaco
Product Description
Research and Development
Product Development Activities
Mid-Stage Products (Phase II)
Comparative Analysis
Mocetinostat: Mirati Therapeutic
Product Description
Research and Development
Product Development Activities
Quisinostat: Janssen
Product Description
Research and Development
Product Development Activities
VRx-3996: Viracta Therapeutics
Product Description
Research and Development
Product Development Activities
Sulforadex: Evgen Pharma
Product Description
Research and Development
Product Development Activities
CHR 5154: Chroma Therapeutics
Product Description
Research and Development
Product Development Activities
CUDC 907: Curis
Product Description
Research and Development
Product Development Activities
Ricolinostat: Celgene Corporation
Product Description
Research and Development
Product Development Activities
Remetinostat: TetraLogic Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Abexinostat: Celera Genomics Group
Product Description
Research and Development
Product Development Activities
Resminostat: 4SC
Product Description
Research and Development
Product Development Activities
FRM 0334: FORUM Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I)
Comparative Analysis
Citarinostat: Celgene Corporation
Product Description
Research and Development
Product Development Activities
AR-42: Arno Therapeutics
Product Description
Research and Development
Product Development Activities
EDO S101: Mundipharma International
Product Description
Research and Development
Product Development Activities
Pre-clinical Products
Comparative Analysis
PCI-34051: Pharmacyclics
Product Description
Research and Development
Product Development Activities
HG 3001: HitGen
Product Description
Research and Development
Product Development Activities
CG-1255: CircaGen Pharmaceutical
Product Description
Research and Development
Product Development Activities
CG-1521: CircaGen Pharmaceutical
Product Description
Research and Development
Product Development Activities
Trichostatin A: Errant Gene Therapeutics
Product Description
Research and Development
Product Development Activities
QTX-125: Quimatryx
Product Description
Research and Development
Product Development Activities
QTX-153: Quimatryx
Product Description
Research and Development
Product Development Activities
ACY 1083: Regenacy Pharmaceuticals
Product Description
Research and Development
Product Development Activities
ACY-738: Celgene Corporation
Product Description
Research and Development
Product Development Activities
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Institutional Products
Inactive Products
Comparative Analysis
Market Drivers and Barriers
Appendix
LIST OF TABLES
Table 1: Active Pipeline Coverage by Indication
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Dormant Products
Table 13: Discontinued Products
Table 1: Active Pipeline Coverage by Indication
Table 2: Marketed and Pipeline HDAC Inhibitors
Table 3: Total Products for HDAC Inhibitors
Table 4: Late Stage Products (Phase III)
Table 5: Mid Stage Products (Phase II)
Table 6: Pre-clinical Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Dormant Products
Table 13: Discontinued Products
LIST OF FIGURES
Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II)
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products
Figure 1: Structure of HDAC Inhibitors
Figure 2: Mechanism of HDAC Inhibitors
Figure 3: Marketed and Pipeline HDAC Inhibitors
Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
Figure 5: Market Evolution (2015-2023)
Figure 6: Total Active Products for HDAC Inhibitors
Figure 7: Total Products for HDAC Inhibitors
Figure 8: Late Stage Products (Phase III)
Figure 9: Entinostat Forecasted Sales (2019-2023)
Figure 10: Mid Stage Products (Phase II)
Figure 11: Early Stage Products (Phase I)
Figure 12: Pre-clinical Products
Figure 13: Assessment by Monotherapy Products
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Inactive Products
